Price Chart

Profile

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company’s programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
URL https://www.enterothera.com
Investor Relations URL https://enterothera.com/investors/overview
HQ State/Province Florida
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 14, 2025 (est.)
Last Earnings Release Nov. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company’s programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
URL https://www.enterothera.com
Investor Relations URL https://enterothera.com/investors/overview
HQ State/Province Florida
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 14, 2025 (est.)
Last Earnings Release Nov. 13, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A